Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | SGK1 | O00141 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.32 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786399 | 0.95 | ALOX5AP (0.41) | ALOX5APFEN1SGK1PIM1PIM3 | |
| Formic Acid SCHEMBL1789053 | 0.90 | KDM4E (0.40) | ALOX5APFEN1SGK1MERTKCHEK1 | |
| SCHEMBL1785404 | 0.85 | KDM4E (0.43) | ALOX5APFEN1SGK1PIM1HTR1A | |
| SCHEMBL3124995 | 0.84 | MERTK (0.34) | MERTKTNK2 | |
| SCHEMBL1787745 | 0.84 | AURKA (0.36) | MERTKCHEK1TNK2EGFR | |
| SCHEMBL3125001 | 0.84 | AURKA (0.36) | MERTKCHEK1TNK2EGFR | |
| SCHEMBL14467227 | 0.84 | AURKA (0.36) | MERTKCHEK1TNK2EGFR | |
| SCHEMBL4788723 | 0.82 | MERTK (0.34) | MERTKCHEK1TNK2EGFR | |
| SCHEMBL1787400 | 0.82 | EGFR (0.34) | MERTKTNK2EGFR | |
| SCHEMBL1785336 | 0.81 | MERTK (0.37) | MERTKCHEK1TNK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, TK2, TPMT | ALOX5AP 602/4885FEN1 18/4885SGK1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.